Delisting risk
Inovio Pharmaceuticals
Develops DNA medicines and CELLECTRA devices, led by INO-3107 for recurrent respiratory papillomatosis.
$1.29
After-hours close0.00 (0.00%)
At close$1.29(+2.38%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.20 | — | — |
| Aug 2026 | −$0.22 | −$0.07 | +67.7% |
| May 2026 | −$0.30 | −$0.28 | +6.7% |
| Mar 2026 | −$0.37 | $0.31 | +183.8% |
| Nov 2025 | −$0.51 | −$0.44 | +13.7% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | −$0.20 | — | — | $2.3M | — | — |
| Aug 12, 2026 | −$0.22 | −$0.07 | +67.7% | $533.3K | — | — |
| May 13, 2026 | −$0.30 | −$0.28 | +6.7% | $333.3K | — | — |
| Mar 12, 2026 | −$0.37 | $0.31 | +183.8% | $333.3K | — | — |
| Nov 10, 2025 | −$0.51 | −$0.44 | +13.7% | — | — | — |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 12, 2025 | ||||||
| May 13, 2025 | ||||||
| Mar 18, 2025 | ||||||
| Nov 14, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 13, 2024 | ||||||
| Mar 6, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 9, 2023 | ||||||
| May 10, 2023 | ||||||
| Mar 1, 2023 | ||||||
| Nov 8, 2022 | ||||||
| Aug 9, 2022 | ||||||
| May 10, 2022 | ||||||
| Mar 1, 2022 | ||||||
| Nov 9, 2021 | ||||||
| Aug 9, 2021 | ||||||
| May 10, 2021 | ||||||
| Mar 1, 2021 | ||||||
| Nov 9, 2020 | ||||||
| Aug 10, 2020 | ||||||
| May 11, 2020 | ||||||
| Mar 12, 2020 | ||||||
| Nov 12, 2019 | ||||||
| Aug 8, 2019 | ||||||
| May 9, 2019 | ||||||
| Mar 12, 2019 | ||||||
| Nov 8, 2018 | ||||||
| Aug 7, 2018 | ||||||
| May 9, 2018 | ||||||
| Mar 14, 2018 | ||||||
| Nov 8, 2017 | ||||||
| Aug 8, 2017 | ||||||
| May 10, 2017 | ||||||
| Mar 15, 2017 | ||||||
| Nov 9, 2016 | ||||||
| Aug 8, 2016 | ||||||
| May 9, 2016 | ||||||
| Mar 14, 2016 | ||||||
| Nov 9, 2015 | ||||||
| Aug 10, 2015 | ||||||